Form 6-K GENMAB A/S For: Jun 11

Thu, 11 Jun 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260611/26634957.html

Form 6-K GENMAB A/S For: Jun 11

Thu, 11 Jun 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260611/26634957.html

Form 6-K GENMAB A/S For: Jun 11

Thu, 11 Jun 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260611/26634957.html

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Thu, 11 Jun 2026 13:16:50 -0400

Company Announcement

COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to employees of the Company and the Company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,616.50.

The restricted stock

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Thu, 11 Jun 2026 13:16:50 -0400

Company Announcement

The restricted stock

Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment

Thu, 11 Jun 2026 10:46:39 -0400

Genmab A/S (NASDAQ: GMAB) presented subgroup analysis data from its Phase 3 EPCORE FL-1 trial at the European Hematology Association Congress. The analysis examined epcoritamab combined with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.

The trial randomized 481 patients, with 243 receiving the epcoritamab combination and 238 receiving rituximab and lenalidomide alone. The subgroup analysis evaluated treatment benefits across different patient risk categories, including Follicular Lymphoma International Prognostic Index scores and disease progression patterns.

Progression-free survival benefits favored the epcoritamab combination across all analyzed subgroups. Hazard ratios remained below 0.3 for patients with FLIPI scores of 0-2 (0.18)

Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment

Thu, 11 Jun 2026 10:46:39 -0400

Progression-free survival benefits favored the epcoritamab combination across all analyzed subgroups. Hazard ratios remained below 0.3 for patients with FLIPI scores of 0-2 (0.18)

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Media Release

COPENHAGEN, Denmark; June 11, 2026

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE^® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R²) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting
Epcoritamab in combination with R² demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors
Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Media Release

COPENHAGEN, Denmark; June 11, 2026

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE^® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R²) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting
Epcoritamab in combination with R² demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors
Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting
Epcoritamab in combination with R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors
Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting

Epcoritamab in combination with R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors

Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting

Epcoritamab in combination with R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors

Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Thu, 11 Jun 2026 10:45:00 -0400

Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this trial of relapsed or refractory (R/R) follicular lymphoma (FL) patients treated in the second-line or later setting

Epcoritamab in combination with R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors

Data were presented during an oral presentation at the 2026 European Hematology Association (EHA) Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today

Form 6-K GENMAB A/S For: May 29

Fri, 29 May 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260529/26576010.html

Form 6-K GENMAB A/S For: May 29

Fri, 29 May 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260529/26576010.html

Form 6-K GENMAB A/S For: May 29

Fri, 29 May 2026 16:41:00 -0400
si-local-file:///var/storage/secattach/20260529/26576010.html

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Fri, 29 May 2026 16:34:52 -0400

Company Announcement

COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Fri, 29 May 2026 16:34:52 -0400

Company Announcement

COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Fri, 29 May 2026 16:34:52 -0400

Company Announcement

COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Fri, 29 May 2026 16:34:52 -0400

Company Announcement

COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company

Truist Securities Assumes Genmab A/S (GMAB) at Buy

Wed, 27 May 2026 06:09:12 -0400

Truist Securities analyst Gregory Renza assumes coverage on Genmab A/S (NASDAQ: GMAB) with a Buy rating and a price target of $40.00.
The analyst comments "We assume coverage at Buy (unchanged) and lower our PT to $40 (from $48). Our thesis centers on GMAB's transition toward a commercially driven platform, supported by three lead assets with up to seven key readouts in 2026. We view Epkinly's DLBCL-2/-4 outcomes as pivotal for franchise expansion, with Rina-S and petosemtamab carrying potential for best-/first-in-class positioning in ovarian cancer and HNSCC, respectively. While Darzalex and broader royalty business should remain serviceable in the near term,

Truist Securities Assumes Genmab A/S (GMAB) at Buy

Wed, 27 May 2026 06:09:12 -0400

Truist Securities analyst Gregory Renza assumes coverage on Genmab A/S (NASDAQ: GMAB) with a Buy rating and a price target of $40.00.
The analyst comments "We assume coverage at Buy (unchanged) and lower our PT to $40 (from $48). Our thesis centers on GMAB's transition toward a commercially driven platform, supported by three lead assets with up to seven key readouts in 2026. We view Epkinly's DLBCL-2/-4 outcomes as pivotal for franchise expansion, with Rina-S and petosemtamab carrying potential for best-/first-in-class positioning in ovarian cancer and HNSCC, respectively. While Darzalex and broader royalty business should remain serviceable in the near term,

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 15 May 2026 13:05:00 -0400
si-local-file:///var/storage/secattach/20260515/26503098.html

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 15 May 2026 13:05:00 -0400
si-local-file:///var/storage/secattach/20260515/26503098.html

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Fri, 15 May 2026 13:05:00 -0400
si-local-file:///var/storage/secattach/20260515/26503098.html

StreetInsider.com News Articles

Form 6-K GENMAB A/S For: Jun 11

Form 6-K GENMAB A/S For: Jun 11

Form 6-K GENMAB A/S For: Jun 11

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment

Genmab presents positive EPCORE FL-1 subgroup data for lymphoma treatment

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Across Relapsed or Refractory (R/R

Form 6-K GENMAB A/S For: May 29

Form 6-K GENMAB A/S For: May 29

Form 6-K GENMAB A/S For: May 29

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Truist Securities Assumes Genmab A/S (GMAB) at Buy

Truist Securities Assumes Genmab A/S (GMAB) at Buy

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD

Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD